Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Comparative effects of SGLT2 inhibitors, pioglitazone, DPP-4 inhibitors, and sulfonylureas on dementia risk in type 2 diabetes.
2026. nov. 3.· The journal of prevention of Alzheimer's disease· PUBMED
Publikáció
Severe Infection Outcomes With SGLT2 Versus DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Active-Comparator Meta-Analysis of Real-World Cohorts.
2026. nov. 1.· Endocrinology, diabetes & metabolism· PUBMED
Publikáció
Challenge-Oriented Decision Tree for Analytical Method Selection in Metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Triple Antidiabetic Fixed-Dose Combinations in Pharmaceutical Dosage Forms.
2026. nov. 1.· Biomedical chromatography : BMC· PUBMED
Publikáció
Comparative Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors on Sepsis in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
2026. okt. 30.· International journal of chronic obstructive pulmonary disease· PUBMED
Publikáció
Integrating QSAR, molecular dynamics and MM-GBSA to re-rank natural product-derived DPP4 candidates from virtual screening.
2026. okt. 29.· SAR and QSAR in environmental research· PUBMED
Publikáció
Use of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations.
2026. okt. 26.· Clinical pharmacology and therapeutics· PUBMED
Publikáció
Key safety outcomes of SGLT2 inhibitors versus DPP-4 inhibitors in general and vulnerable participants with T2DM: A target trial emulation study.
2026. okt. 19.· Diabetic medicine : a journal of the British Diabetic Association· PUBMED
Publikáció
Biliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors.
2026. okt. 16.· Journal of clinical medicine· PUBMED
Publikáció
Exploring the impact of GLP-1 analogues and DPP-4 inhibitors on cognitive decline in elderly patients with type 2 diabetes: a competing risks analysis from a real-world cohort.
2026. okt. 15.· Frontiers in pharmacology· PUBMED
Publikáció
C-Peptide Changes and Glycemic Response During DPP-4 Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: The Role of Baseline C-Peptide.
2026. okt. 7.· Medicina (Kaunas, Lithuania)· PUBMED
Publikáció
SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis.
2026. okt. 5.· Diabetology international· PUBMED
Publikáció
GLP-1 Receptor Agonists Versus DPP-4 Inhibitors and Incident Dementia Risk in COVID-19 Survivors with Type 2 Diabetes: A Target Trial Emulation Study.
2026. szept. 30.· Drug design, development and therapy· PUBMED
Publikáció
GLP-1 receptor agonists versus DPP-4 inhibitors after curative resection of hepatocellular carcinoma in patients with type 2 diabetes.
2026. szept. 29.· Gut· PUBMED
Publikáció
Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP-4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation.
2026. szept. 28.· Clinical pharmacology and therapeutics· PUBMED
Publikáció
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
2026. szept. 26.· Internal and emergency medicine· PUBMED
Publikáció
The effect of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors on stroke risk in type 2 diabetes: a nationwide longitudinal cohort study in Sweden with contextualisation analysis.
2026. szept. 23.· EClinicalMedicine· PUBMED
Publikáció
Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease.
2026. szept. 23.· Advances in therapy· PUBMED
Publikáció
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity: comment.
2026. szept. 19.· Internal and emergency medicine· PUBMED
Publikáció
Proteomic profiling reveals that DPP4 overexpression increases cell adhesion, inhibits cell migration, and restores androgen sensitivity in prostate cancer.
2026. szept. 16.· Bioscience reports· PUBMED
Publikáció
GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetes.
2026. szept. 7.· Journal of neurology· PUBMED
Publikáció
SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes.
2026. szept. 4.· Frontiers in endocrinology· PUBMED
Publikáció
Initiation of SGLT2 Inhibitors Versus DPP-4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims-Based Active-Comparator New-User Study.
2026. szept. 1.· Diabetes, obesity & metabolism· PUBMED
Publikáció
Cost-utility analysis of loxenatide versus DPP-4 inhibitors in Chinese patients with type 2 diabetes at high cardiovascular risk.
2026. aug. 28.· Frontiers in public health· PUBMED
Publikáció
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
2026. aug. 20.· Internal and emergency medicine· PUBMED
Publikáció
Association of GLP-1 receptor agonists, SGLT 2 inhibitors, DPP-4 inhibitors, and sulfonylureas with incident cancer in type 2 diabetes.
2026. aug. 17.· Diabetes research and clinical practice· PUBMED
Publikáció
Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study.
2026. aug. 11.· Drug design, development and therapy· PUBMED
Publikáció
Sex-specific cardiometabolic remodeling induced by DPP-4 inhibition under high-fat diet: insights from cardiac proteomics.
2026. aug. 10.· Nutrition, metabolism, and cardiovascular diseases : NMCD· PUBMED
Publikáció
Glycemic Outcomes After Switching from SGLT2 Inhibitors to DPP-4 Inhibitors in Type 2 Diabetes, with a Comparison of Teneligliptin and Other Agents: A Retrospective Cohort Study.
2026. aug. 6.· Medicina (Kaunas, Lithuania)· PUBMED
Publikáció
Targeting the non-enzymatic function of DPP4 via a nanobody inhibits cerebral cavernous malformation progression.
2026. aug. 5.· Journal of nanobiotechnology· PUBMED